CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE

被引：0
|
作者：
Oriol, A. [1 ]
Steinmetz, T. [2 ]
Patel, V [3 ]
Kutikova, L. [4 ]
Schmidt, N. [5 ]
Hennies, N. [5 ]
Thiess, A. [5 ]
Kostev, K. [5 ]
Leleu, X. [6 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Inst Catala Oncol, Barcelona, Spain
[2] MVZ Hematol & Oncol Cologne, Cologne, Germany
[3] Amgen Europe GmbH, London, England
[4] Amgen Europe GmbH, Rotkreuz, Switzerland
[5] IQVIA Commercial GmbH & Co OHG, Frankfurt, Germany
[6] CHU Poitiers, Hosp La Miletrie, Poitiers, France
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN318
引用
收藏
页码：S497 / S498
页数：2
相关论文
共 50 条
  • [1] Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Anum, Babar
    Hina, Zubair
    Mainoma, Bano
    Sana, Rafique
    Arzu, Shahid
    Maham, Babar
    Waleed, Madeeha S.
    Arslan, Inayat
    Danish, Safi
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S29 - S29
  • [2] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [3] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    DerSarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert M.
    [J]. BLOOD, 2017, 130
  • [4] Patient Characteristics, Treatment Patterns and Outcomes Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients in Japan
    Jun, Gyungjin
    Luptakova, Katarina
    Koizumi, Hiroo
    Iwasaki, Kosuke
    Hiroi, Shinzo
    Soeda, Junpei
    [J]. BLOOD, 2016, 128 (22)
  • [5] Therapy of relapsed and/or refractory multiple myeloma (RRMM)
    Engelhardt, M.
    Waesch, R.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 14 - 14
  • [6] Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Romanus, Dorothy
    DasMahapatra, Pronabesh
    Hoole, Michael
    Lowe, Maria
    Curran, Chris
    Campbell, Scott
    Bell, Jill A.
    [J]. ONCOLOGIST, 2019, 24 (11): : 1479 - 1487
  • [7] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    [J]. BLOOD, 2020, 136
  • [8] A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM)
    Kumar, Swarup
    Clark, Jackson
    Alvarez-Soto, Alvaro
    El Warrak, Samantha
    Kumar, Shruthi
    Braish, Julie
    Reddy, Aswanth
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S190 - S191
  • [9] PATIENT PREFERENCES REGARDING TREATMENT OPTIONS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
    Bauer, S.
    Mueller, S.
    Ratsch, B.
    Pitura, S.
    Probst, L.
    van Eickels, D.
    Wilke, T.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A451 - A451
  • [10] Characteristics, Treatment Patterns, and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in North America (NA) and Europe: Findings from the PREAMBLE Study
    Vij, Ravi
    Chen, Clara
    Davis, Catherine
    Kim, Hyang
    Durie, Brian
    Cook, Gordon
    Goldschmidt, Hartmut
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S252 - S252
12345